Abstract E-0084 Table 2 mRS 0-2 in Solitaire ASPECTS 8-10 patients
Trial
IA Group mRS 0-2
SWIFT PRIME
67% (n = 71)
REVASCAT
50% (n = 50)
ESCAPE
55.5% (n =128)
EXTEND-IA
N/A
Weighted Solitaire Campbell
57.7
%
(n
=
249
)